Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.
Van Alsten SC, Dunn MR, Hamilton AM, Ivory JM, Gao X, Kirk EL, Nsonwu-Farley JS, Carey LA, Abdou Y, Reeder-Hayes KE, Roberson ML, Wheeler SB, Emerson MA, Hyslop T, Troester MA. Van Alsten SC, et al. Among authors: abdou y. Cancer Epidemiol Biomarkers Prev. 2024 May 1;33(5):654-661. doi: 10.1158/1055-9965.EPI-23-1201. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38270534
The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients.
Hamilton AM, Hurson AN, Olsson LT, Walens A, Nsonwu-Farley J, Kirk EL, Abdou Y, Downs-Canner SM, Serody JS, Perou CM, Calhoun BC, Troester MA, Hoadley KA. Hamilton AM, et al. Among authors: abdou y. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1341-1350. doi: 10.1158/1055-9965.EPI-21-1312. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35437570 Free PMC article.
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects.
Nakamura ZM, Deal AM, Park EM, Stanton KE, Lopez YE, Quillen LJ, O'Hare Kelly E, Heiling HM, Nyrop KA, Ray EM, Dees EC, Reeder-Hayes KE, Jolly TA, Carey LA, Abdou Y, Olajide OA, Rauch JK, Joseph R, Copeland A, McNamara MA, Ahles TA, Muss HB. Nakamura ZM, et al. Among authors: abdou y. Cancer Med. 2023 Apr;12(7):8172-8183. doi: 10.1002/cam4.5619. Epub 2023 Jan 16. Cancer Med. 2023. PMID: 36645168 Free PMC article. Clinical Trial.
BIRC5 expression by race, age and clinical factors in breast cancer patients.
Hamilton AM, Walens A, Van Alsten SC, Olsson LT, Nsonwu-Farley J, Gao X, Kirk EL, Perou CM, Carey LA, Troester MA, Abdou Y. Hamilton AM, et al. Among authors: abdou y. Breast Cancer Res. 2024 Mar 21;26(1):50. doi: 10.1186/s13058-024-01792-y. Breast Cancer Res. 2024. PMID: 38515208 Free PMC article.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M. Schettini F, et al. Among authors: abdou y. Cancer. 2024 May 16. doi: 10.1002/cncr.35323. Online ahead of print. Cancer. 2024. PMID: 38752572
43 results